News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
768,957 Results
Type
Article (59284)
Company Profile (310)
Press Release (709363)
Multimedia
Podcasts (84)
Webinars (13)
Section
Business (218856)
Career Advice (2887)
Deals (37572)
Drug Delivery (121)
Drug Development (86842)
Employer Resources (185)
FDA (17398)
Job Trends (16295)
News (371883)
Policy (36426)
Tag
Academia (2946)
Academic (1)
Accelerated approval (5)
Adcomms (27)
Allergies (93)
Alliances (53507)
ALS (98)
Alzheimer's disease (1487)
Antibody-drug conjugate (ADC) (143)
Approvals (17374)
Artificial intelligence (287)
Autoimmune disease (25)
Automation (16)
Bankruptcy (392)
Best Places to Work (12368)
BIOSECURE Act (20)
Biosimilars (114)
Biotechnology (214)
Bladder cancer (83)
Brain cancer (31)
Breast cancer (298)
Cancer (2392)
Cardiovascular disease (197)
Career advice (2424)
Career pathing (34)
CAR-T (164)
Cell therapy (457)
Cervical cancer (21)
Clinical research (70325)
Collaboration (890)
Company closure (1)
Compensation (543)
Complete response letters (26)
COVID-19 (2820)
CRISPR (47)
C-suite (262)
Cystic fibrosis (103)
Data (2261)
Decentralized trials (2)
Denatured (31)
Depression (55)
Diabetes (287)
Diagnostics (6778)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (129)
Drug pricing (119)
Drug shortages (30)
Duchenne muscular dystrophy (101)
Earnings (90001)
Editorial (45)
Employer branding (24)
Employer resources (158)
Events (121501)
Executive appointments (769)
FDA (18716)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (792)
Gene editing (117)
Generative AI (26)
Gene therapy (337)
GLP-1 (821)
Government (4927)
Grass and pollen (6)
Guidances (67)
Healthcare (20426)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (138)
Indications (30)
Infectious disease (2976)
Inflammatory bowel disease (151)
Inflation Reduction Act (9)
Influenza (54)
Intellectual property (99)
Interviews (556)
IPO (17146)
IRA (48)
Job creations (4357)
Job search strategy (2002)
Kidney cancer (11)
Labor market (38)
Layoffs (529)
Leadership (24)
Legal (9015)
Liver cancer (81)
Lung cancer (343)
Lymphoma (156)
Machine learning (7)
Management (62)
Manufacturing (327)
MASH (74)
Medical device (14490)
Medtech (14495)
Mergers & acquisitions (20968)
Metabolic disorders (760)
Multiple sclerosis (86)
NASH (23)
Neurodegenerative disease (108)
Neuropsychiatric disorders (33)
Neuroscience (2081)
NextGen: Class of 2025 (7261)
Non-profit (4947)
Now hiring (39)
Obesity (407)
Opinion (256)
Ovarian cancer (77)
Pain (97)
Pancreatic cancer (86)
Parkinson's disease (159)
Partnered (21)
Patents (247)
Patient recruitment (116)
Peanut (51)
People (62819)
Pharmaceutical (73)
Pharmacy benefit managers (19)
Phase I (21838)
Phase II (30794)
Phase III (23069)
Pipeline (1239)
Policy (161)
Postmarket research (3019)
Preclinical (9433)
Press Release (72)
Prostate cancer (112)
Psychedelics (38)
Radiopharmaceuticals (263)
Rare diseases (414)
Real estate (6617)
Recruiting (72)
Regulatory (24752)
Reports (47)
Research institute (2592)
Resumes & cover letters (454)
Rett syndrome (5)
RNA editing (5)
RSV (46)
Schizophrenia (81)
Series A (138)
Series B (90)
Service/supplier (15)
Sickle cell disease (58)
Special edition (16)
Spinal muscular atrophy (161)
Sponsored (32)
Startups (3968)
State (2)
Stomach cancer (16)
Supply chain (74)
Tariffs (44)
The Weekly (51)
Vaccines (784)
Venture capitalists (43)
Weight loss (285)
Women's health (38)
Worklife (19)
Date
Today (143)
Last 7 days (931)
Last 30 days (2762)
Last 365 days (34277)
2025 (11310)
2024 (36926)
2023 (41936)
2022 (53214)
2021 (57977)
2020 (56904)
2019 (50262)
2018 (38149)
2017 (35040)
2016 (35240)
2015 (41252)
2014 (35304)
2013 (30869)
2012 (32977)
2011 (33543)
2010 (32164)
Location
Africa (955)
Alabama (54)
Alaska (7)
Arizona (249)
Arkansas (14)
Asia (43741)
Australia (7881)
California (6288)
Canada (2049)
China (554)
Colorado (278)
Connecticut (297)
Delaware (155)
Europe (97379)
Florida (927)
Georgia (217)
Idaho (63)
Illinois (596)
India (27)
Indiana (320)
Iowa (11)
Japan (167)
Kansas (108)
Kentucky (26)
Louisiana (11)
Maine (62)
Maryland (944)
Massachusetts (4759)
Michigan (229)
Minnesota (413)
Mississippi (2)
Missouri (89)
Montana (29)
Nebraska (25)
Nevada (65)
New Hampshire (68)
New Jersey (1785)
New Mexico (30)
New York (1792)
North Carolina (1061)
North Dakota (8)
Northern California (2733)
Ohio (209)
Oklahoma (14)
Oregon (38)
Pennsylvania (1404)
Puerto Rico (13)
Rhode Island (35)
South America (1345)
South Carolina (24)
South Dakota (1)
Southern California (2355)
Tennessee (104)
Texas (931)
United States (24028)
Utah (188)
Virginia (154)
Washington D.C. (68)
Washington State (578)
West Virginia (3)
Wisconsin (58)
768,957 Results for "merz aesthetics formerly known as bioform medical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Merz Aesthetics® Announces Salma Hayek Pinault as First-Ever Global Brand Ambassador for Ultherapy PRIME®, the Next Generation Platform for Nonsurgical Skin Lifting Treatments
April 9, 2025
·
5 min read
Press Releases
Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments
September 23, 2024
·
6 min read
Earnings
AbbVie’s Marketing Misstep Further Erodes 2024 Aesthetics Sales
AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing misstep comes as the company’s aesthetics franchise faces broader pressures.
February 3, 2025
·
4 min read
·
Annalee Armstrong
Job Trends
Merz Enters Asset Purchase Agreement With a US-Based Biotech Company
Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics.
April 2, 2024
·
3 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Deals
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
Acorda Therapeutics, Inc. announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.
April 1, 2024
·
8 min read
Press Releases
FDA Classifies Q’Apel Medical Inc.'s Worldwide Medical Device Recall and Discontinuation of its 072 Aspiration System (Hippo) as Class I
April 18, 2025
·
4 min read
Bio NC
Merz Aesthetics® Announces Teyana Taylor as New Xeomin® (incobotulinumtoxinA) Brand Partner
Merz Aesthetics®, the world’s largest dedicated medical aesthetics business, today announced Teyana Taylor as the latest Xeomin® (incobotulinumtoxinA) brand partner.
November 1, 2022
·
9 min read
Deals
Acorda Joins Growing Group of Biotechs Filing for Bankruptcy, Divests Assets to Merz
Acorda Therapeutics becomes the latest biotechnology company in 2024 to go bankrupt and shutter its business, following years of financial difficulty. Merz Therapeutics will acquire two commercial medicines from Acorda for $185 million.
April 3, 2024
·
2 min read
·
Tristan Manalac
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
1 of 76,896
Next
